Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 3/20 | 0.35 |
| ▸ | HTR1B | P28222 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 15/20 | 0.34 |
| ▸ | DRD2 | P14416 | 4/20 | 0.34 |
| ▸ | DRD4 | P21917 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30299330 | 0.92 | GAA (0.34) | GAAHPGDSMN1; SMN2 | |
| SCHEMBL30090537 | 0.87 | TNIK (0.36) | GAA | |
| SCHEMBL29928562 | 0.86 | CDK4 (0.31) | GAAHPGDSMN1; SMN2 | |
| SCHEMBL30299336 | 0.84 | JAK2 (0.35) | GAAHPGDSMN1; SMN2 | |
| SCHEMBL30299337 | 0.83 | FPR1 (0.37) | — | |
| SCHEMBL30299377 | 0.82 | PDE3B (0.34) | GAAHPGDSMN1; SMN2 | |
| SCHEMBL30299371 | 0.79 | ALDH1A1 (0.43) | GAA | |
| SCHEMBL29929683 | 0.79 | AXL (0.40) | SMN1; SMN2 | |
| SCHEMBL30090486 | 0.78 | KCNH2 (0.39) | — | |
| SCHEMBL30299303 | 0.78 | CYP17A1 (0.36) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | disclosed |